Zoll Medical yesterday said it agreed to acquire Philips‘ (NYSE:PHG) InnerCool business and its catheter-based endovascular and surface temperature management technologies.
The acquired devices, all cleared by the FDA, include InnerCool’s RTx endovascular system, the Accutrol catheter and the CoolRepeat and STx surface cooling systems, according to a press release.
"The combination of InnerCool with Zoll’s existing temperature management technologies expands Zoll’s position as the leading provider of high-technology systems for precise temperature management," Zoll president James Palazzolo said in prepared remarks. "This underscores our commitment to provide a wide variety of clinical temperature therapies based on physician preference and clinical judgment."
The InnerCool assets also provide Zoll with a rich patent portfolio and pipeline of future products, according to the release. InnerCool will be integrated into Zoll’s Temperature Management business in San Jose, California, Zoll said.
A company spokeswoman did not immediately reply to a request for more details on the acquisition.